A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

NCT00950300 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

596

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: 5-Fluorouracil
DRUG: Cyclophosphamide
DRUG: Docetaxel
DRUG: Epirubicin
DRUG: Herceptin IV [trastuzumab]
DRUG: Herceptin SC [trastuzumab]

Sponsor

Hoffmann-La Roche